+62%

est. 2Y upside i

HealthcareHR TechSeries A

Rank

#847

Sector

Healthtech, Workforce Management Software

Est. Liquidity

~5Y

Data Quality

Data: Low

M7 Health offers speculative upside with a probability-weighted 2-year return of ~62%, but the bear case (-100%) is material due to preference overhang.

Last updated: July 19, 2026

Bull (25%)+225%

Revenue reaches $12.7M by month 24; exit multiple expands to 15x (IPO window or category leadership). Implied exit value $190.5M vs $50M entry, net of 20% dilution yields 224.8% upside.

Base (50%)+62%

Revenue reaches $12.7M; exit multiple converges to 7x (within comp range). Implied exit value $88.9M vs $50M entry, net of 20% dilution yields 62.2% upside.

Bear (25%)-100%

Revenue falls short or multiple compresses; implied exit value below $17M total funding. Preference stack absorbs all proceeds, common stock returns -100%.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

3400%

Total funding $17M on estimated $50M valuation gives 34% preference overhang; if exit value < $17M, common stock recovers nothing.

Dilution Risk

high

With $10M Series A raised in July 2025 and estimated 15-18 month runway, a follow-on round within 24 months is likely, diluting common shareholders by 15-25%.

Secondary Liquidity

none

No secondary market activity reported; illiquid private shares with no near-term exit path.

Questions to Ask at the Interview

Strategic questions based on M7 Health's data — designed to show you've done your homework.

  • 1

    “What is the current ARR and net revenue retention?”

  • 2

    “How does M7 Health defend against incumbent scheduling platforms like QGenda?”

  • 3

    “What is the expected timeline to a liquidity event, and does the company plan to raise additional capital?”

Community

Valuation Sentiment

Our model estimates +62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.